Tenapanor is an orally active, locally acting sodium/hydrogen exchanger 3 (NHE3) inhibitor used to reduce intestinal sodium absorption and increase fluid secretion, primarily indicated for managing irritable… Read more










Tenapanor is an orally active, locally acting sodium/hydrogen exchanger 3 (NHE3) inhibitor used to reduce intestinal sodium absorption and increase fluid secretion, primarily indicated for managing irritable bowel syndrome with constipation. This category features a comprehensive selection of reference standards for the Tenapanor active pharmaceutical ingredient (API), alongside its pharmacopeial and non-pharmacopeial impurities. Laboratories utilize these high-quality compounds for essential analytical testing, enabling precise impurity profiling, method validation, and rigorous quality control protocols throughout the drug development lifecycle. The inclusion of stable isotope labelled compounds provides critical internal standards for mass spectrometry-based assays, ensuring accurate quantification and characterization of the drug and its related substances in complex matrices. These tools are indispensable for maintaining compliance and achieving reliable results in pharmaceutical research and manufacturing.